NYSE
891.23USD
+4.76 (+0.54%)
We have scored 53 news catalysts on McKesson Corporation (MCK) over the past 12 months. The biggest single-day move next to one of them came Sep 23, 2025, when MCK closed +6.4%: “Dow Jones and Nasdaq futures flat pre Powell speech, OECD forecasts US growth decline”. Coverage across the window leans positive (average ticker sentiment +0.37). Most of the impact sits in sector healthcare and institutional ownership change.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
104.3B
P/E
—
EPS
—
Beta
0.31
52W range
714-999
Day range
882.97–897.46
Open
893.22
Prev close
886.47
Volume
853.1K
Avg volume
1.1M
Dividend
3.40
IPO
1994-11-10
Analysts publish price targets on MCK, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
6 analyst price targets from $845 to $1,050
as of 2026-09-01
The market is 8% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about McKesson Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MCK: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
The reconstruction
The price sits 8% below the median published target and at the 33rd percentile by count, meaning the market leans bearish and explicitly declines to pay for the most optimistic growth assumptions.
What the disagreement turns on
Can the Oncology & Multispecialty segment and GLP-1 distribution sustain growth fast enough to offset the priced-in deceleration of the core pharmaceutical business, and the available unit volume data can test the revenue side but cannot measure the margin impact.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
